logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Rejects Ariad, Merck's Sarcoma Drug Ridaforolimus

Merck-FDA-060512.jpg

Merck & Co. Inc. (MRK) said Tuesday that the U.S. Food and Drug Administration has rejected the new drug application for ridaforolimus, an investigational oral mTOR inhibitor under development for maintenance treatment for patients with metastatic soft tissue or bone sarcoma who have stable disease or better after four or more cycles of chemotherapy.

The FDA stated in its complete response letter that it cannot approve the application in its present form and that additional clinical trial(s) would be needed to further assess safety and efficacy of the drug, according to Whitehouse Station, New Jersey-based Merck.

"Merck remains confident in the potential of ridaforolimus," said Eric Rubin, vice president, Clinical Research Oncology, Merck. "We will continue to work closely with the FDA to define potential paths forward for this investigational therapy."

Merck also said it is in ongoing talks with health authorities in Europe and other countries as part of their application procedures for ridaforolimus and is studying the drug in combination with other mechanisms in several tumor types.

Merck is responsible for the development and commercialization of ridaforolimus in oncology as part of an exclusive license agreement with Ariad Pharmaceuticals, Inc (ARIA).

The FDA's rejection of the NDA for ridaforolimus was on expected line. In March, an FDA advisory panel had voted 13-1 recommending against approval of the drug.

A sarcoma is a type of cancer that develops from certain tissues, like bone or muscle. There are 2 main types of sarcoma: bone sarcomas and soft tissue sarcomas. According to the University of California, San Francisco, about 2,500 new cases are diagnosed annually.

If approved, ridaforolimus would compete with GlaxoSmithKline Plc's (GSK, GSK.L) Votrient, which received FDA approval in April for expanded use on patients with soft-tissue sarcomas who have had chemotherapy.

Merck shares closed Tuesday's regular trading session at $37.50, up 4 cents, and is currently gaining 7 cents in after hours trading. Ariad shares are currently losing 1.67% in after hours trading after closing the day's regular trading session at $16.20, up 57 or 3.65%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Dealing a potentially fatal blow to a last-ditch effort by Republicans to repeal and replace Obamacare, Senator John McCain, R-Ariz., on Friday announced his opposition to a healthcare bill drafted by Senators Lindsey Graham, R-S.C., and Bill Cassidy, R-La. Reiterating his claim that Russian meddling in last year's election is a hoax, President Donald Trump has argued that the biggest influence on the election came from the media. Trump seemed to suggest in a post on Twitter on Friday that his victory in the presidential election came despite the media's... U.S. airlines collected a record $7.1 billion in revenue from fees for checked baggage and for changing or canceling reservations, reflecting a marked increase from 2010, according to a government report. The U.S. Government Accountability Office or GOA said in a report that U.S. airlines' revenue from these two fees increased to $7.1 billion in 2016 from $6.3 billion in 2010, in constant dollars.
comments powered by Disqus
Follow RTT